Budesonide | Market Exclusivity | US | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Budesonide
U.S. EXCLUSIVITIES

PharmaCompass Sponsored Ads

Contact Supplier

Coral Budesonide

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Budesonide

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

67 API Suppliers, 24 USDMF, 27 CEP/COS, 7 JDMF, 7 EU WC, 15 KDMF, 34 NDC API, 43 Listed Suppliers, $ API Reference Price

67 API Suppliers
24 USDMF
27 CEP/COS
7 JDMF
7 EU WC
15 KDMF
34 NDC API
43 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

71 Drugs in Development

71 Drugs in Development

INTERMEDIATES

7 API Suppliers

7 API Suppliers

FINISHED DOSAGE FORMULATIONS

611 FDF Dossiers, 54 FDA Orange Book, 429 Europe, 23 Canada, 13 Australia, 39 South Africa, 53 Listed Dossiers

611 FDF Dossiers
54 FDA Orange Book
429 Europe
23 Canada
13 Australia
39 South Africa
53 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 9MG, AEROSOL, FOAM;RECTAL - 2MG/ACTUATION, SPRAY, METERED;NASAL - 0.032MG/SPRAY, SUSPENSION;INHALATION - 0.25MG/2ML, SUSPENSION;INHALATION - 0.5MG/2ML, SUSPENSION;INHALATION - 1MG/2ML, CAPSULE, DELAYED RELEASE;ORAL - 6MG, CAPSULE, DELAYED RELEASE;ORAL - 9MG, CAPSULE, DELAYED RELEASE;ORAL - 3MG, AEROSOL, METERED;INHALATION - 0.08MG/INH;0.0045MG/INH, AEROSOL, METERED;INHALATION - 0.16MG/INH;0.0045MG/INH

TABLET, EXTENDED RELEASE;ORAL - 9MG
AEROSOL, FOAM;RECTAL - 2MG/ACTUATION
SPRAY, METERED;NASAL - 0.032MG/SPRAY
SUSPENSION;INHALATION - 0.25MG/2ML
SUSPENSION;INHALATION - 0.5MG/2ML
SUSPENSION;INHALATION - 1MG/2ML
CAPSULE, DELAYED RELEASE;ORAL - 6MG
CAPSULE, DELAYED RELEASE;ORAL - 9MG
CAPSULE, DELAYED RELEASE;ORAL - 3MG
AEROSOL, METERED;INHALATION - 0.08MG/INH;0.0045MG/INH
AEROSOL, METERED;INHALATION - 0.16MG/INH;0.0045MG/INH

RELATED EXCIPIENT COMPANIES

1 Evonik, 1 Rochem International Inc, 5 SPI Pharma, 2 Seqens, 9 DKSH, 1 Jai Radhe Sales, 10 Gangwal Healthcare, 6 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 ACG Worldwide, 11 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 23 BASF, 1 Clariant, 14 Corel Pharma Chem, 4 DFE Pharma, 3 Doshion Polyscience, 2 Finar, 10 Gangwal Chemicals, 9 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 31 Kerry, 5 Kima Chemical, 6 Lonza Capsugel, 16 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 5 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 18 Roquette, 14 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 4 The Dow Chemical Company, 2 Valens Pharmachem, 2 Vasa Pharmachem, 2 Vertellus

EXCIPIENTS BY APPLICATIONS

67 Coating Systems & Additives, 66 Fillers, Diluents & Binders, 41 Controlled & Modified Release, 33 Thickeners and Stabilizers, 30 Direct Compression, 24 Solubilizers, 20 Film Formers & Plasticizers, 20 Granulation, 19 Lubricants & Glidants, 19 Taste Masking, 18 Topical, 15 Parenteral, 15 Co-Processed Excipients, 11 Disintegrants & Superdisintegrants, 9 Emulsifying Agents, 9 Empty Capsules, 6 Rheology Modifiers, 6 Chewable & Orodispersible Aids, 5 API Stability Enhancers, 5 Coloring Agents, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents

67 Coating Systems & Additives
66 Fillers, Diluents & Binders
41 Controlled & Modified Release
33 Thickeners and Stabilizers
30 Direct Compression
24 Solubilizers
20 Film Formers & Plasticizers
20 Granulation
19 Lubricants & Glidants
19 Taste Masking
18 Topical
15 Parenteral
15 Co-Processed Excipients
11 Disintegrants & Superdisintegrants
9 Emulsifying Agents
9 Empty Capsules
6 Rheology Modifiers
6 Chewable & Orodispersible Aids
5 API Stability Enhancers
5 Coloring Agents
4 Vegetarian Capsules
4 Surfactant & Foaming Agents

DIGITAL CONTENT

5 DATA COMPILATION #PharmaFlow, 1 STOCK RECAP #PipelineProspector, 129 NEWS #PharmaBuzz

5 DATA COMPILATION #PharmaFlow
1 STOCK RECAP #PipelineProspector
129 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

5 US Medicaid Prescriptions, 232 Finished Drug Prices, 37 Annual Reports

5 US Medicaid Prescriptions
232 Finished Drug Prices
37 Annual Reports

MARKET PLACE

18 APIs, 17 FDF Dossiers, 1 EXCIPIENTS

18 APIs
17 FDF Dossiers
1 EXCIPIENTS

PATENTS & EXCLUSIVITIES

53 US Patents, 5 US Exclusivities, 2 Health Canada Patents

53 US Patents
5 US Exclusivities
2 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 4 USP, 13 Others

2 EDQM
4 USP
13 Others

ANALYTICAL

3 BioAnalytical Methods

3 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 3,439 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Name Reset all filters

5 All

01 3CALLIDITAS

02 2TAKEDA PHARMS USA

filter Product Reset all filters

5 All

01 5BUDESONIDE

filter Exclusivity Expiration Date Reset all filters

5 All

01 12024-12-15

02 12027-02-09

03 12028-12-15

04 12030-12-20

05 12031-02-09

filter Exclusivity Code Reset all filters

5 All

01 2NP

02 1ODE-389

03 1ODE-464

04 1ODE-466

Minakem Budesonide

Product Main Page

TAKEDA PHARMS USA

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

BUDESONIDE

Portfolio PDF

Product Web Link

Digital Content

Exclusivity Code

ODE-466

Exclusivity Expiration Date

2031-02-09

Application Number

213976

Product Number

1

Exclusivity Details

01

TAKEDA PHARMS USA

2024 ACI Convention

Not Confirmed

TAKEDA PHARMS USA

Japan

2024 ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : ODE-466

Exclusivity Expiration Date : 2031-02-09

Application Number : 213976

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

CALLIDITAS

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

BUDESONIDE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

NP

Exclusivity Expiration Date

2024-12-15

Application Number

215935

Product Number

1

Exclusivity Details

02

CALLIDITAS

2024 ACI Convention

Not Confirmed

CALLIDITAS

Sweden

2024 ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : NP

Exclusivity Expiration Date : 2024-12-15

Application Number : 215935

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

CALLIDITAS

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

BUDESONIDE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

ODE-464

Exclusivity Expiration Date

2030-12-20

Application Number

215935

Product Number

1

Exclusivity Details

03

CALLIDITAS

2024 ACI Convention

Not Confirmed

CALLIDITAS

Sweden

2024 ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : ODE-464

Exclusivity Expiration Date : 2030-12-20

Application Number : 215935

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

CALLIDITAS

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

BUDESONIDE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

ODE-389

Exclusivity Expiration Date

2028-12-15

Application Number

215935

Product Number

1

Exclusivity Details

04

CALLIDITAS

2024 ACI Convention

Not Confirmed

CALLIDITAS

Sweden

2024 ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : ODE-389

Exclusivity Expiration Date : 2028-12-15

Application Number : 215935

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

TAKEDA PHARMS USA

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

BUDESONIDE

Portfolio PDF

Product Web Link

Digital Content

Exclusivity Code

NP

Exclusivity Expiration Date

2027-02-09

Application Number

213976

Product Number

1

Exclusivity Details

05

TAKEDA PHARMS USA

2024 ACI Convention

Not Confirmed

TAKEDA PHARMS USA

Japan

2024 ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : NP

Exclusivity Expiration Date : 2027-02-09

Application Number : 213976

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?